Depression is a prevalent, frequently recurrent and often chronic syndrome that affects quality of life and overall productivity. About 18 million Americans and 340 million people worldwide are affected from depression. Fourteen groups (n=6) were employed in the present study. Boswellic acid (25 mg/kg/day, p.o) was administered for 12 consecutive days as a test drug. Imipramine (15 mg/kg, p.o.) was injected for 12 days as a standard anti-depressant drug for evaluation of behavioural parameters. The present study concluded Boswellic acid as anti-depressant as suggested by the results obtained. Boswellic acid administration reduces immobility period in TST and FST models reverse Sucrose preference in CUMS group, when compared to normal control. The microsomal lipid peroxidation of polyunsaturated fatty acids (PUFA) produced malondialdehyde (MDA), lipid hydroperoxides. The restraint stress enhances the level of lipid peroxidation, hence increased Malondialdehyde, nitrite and significantly decreased reduced glutathione levels. Several studies reveal Boswellic acid as anti-oxidant. Proving its antioxidant effects, Boswellic acid potentially reduces oxidative stress, by altering malondialdehyde (MDA), nitrite/nitrate and reduced glutathione (GSH) levels, when compared to normal control.